Hero image with Pittsburgh background pittplusme.org/study/1322

STUDY BASICS

Have you been diagnosed with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer? Has your doctor recommended that you start taking brigatinib (brand name Alunbrig) to treat your disease? If so, you may be eligible to participate in this study to help researchers study how often pulmonary (lung) issues such as breathing issues, pneumonia, etc. occur to patients taking brigatinib.


IRB:
  STUDY19040116 - 18-042 Pulmonary Physiology and Systemic Inflammatory Signature Investigations in Early Onset Pulmonary Events Associated with Brigatinib use in Non-Small Cell Lung Cancer and Other Diseases

Age Range
AGE:   18 and up

Duration VISITS:  A screening visit and 4 in-person study visits

Location LOCATION: 
UPMC Cancer Center
Compensation COMPENSATION: 

NONE

Phone Number PHONE NUMBER:
1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In
Search Icon pittplusme.org/study/1322
OR
Phone Number PHONE NUMBER:
1-866-438-8230

PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe share tweet